85 related articles for article (PubMed ID: 9483213)
1. [Immunohistochemistry of biomolecular markers of early thyroid cancer].
Paltsev MA; Kogan EA; Tuntsova OI
Arkh Patol; 1997; 59(6):18-23. PubMed ID: 9483213
[TBL] [Abstract][Full Text] [Related]
2. [Morphologic and molecular-genetic characteristics of carcinoma, adenoma and surrounding tissue of the thyroid gland].
Pal'tsev MA; Kogan EA; Tuntsova OI; Severin ES; Silaeva SA; Golenchenko VA
Arkh Patol; 1998; 60(3):5-10. PubMed ID: 9702292
[TBL] [Abstract][Full Text] [Related]
3. [Role of the MIB-1 proliferative markers in the diagnosis and prognosis of tumors of the thyroid gland].
Ludvíková M; Ryska A; Hovorková E; Pikner R
Cesk Patol; 2002 Jan; 38(1):4-10. PubMed ID: 11933461
[TBL] [Abstract][Full Text] [Related]
4. Role of Ki-67 as a proliferative marker in lesions of thyroid.
Pujani M; Arora B; Pujani M; Singh SK; Tejwani N
Indian J Cancer; 2010; 47(3):304-7. PubMed ID: 20587907
[TBL] [Abstract][Full Text] [Related]
5. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
6. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
7. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
8. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 and AgNOR proliferative markers as diagnostic adjuncts to fine needle aspiration cytology of thyroid follicular lesions.
Mehrotra A; Goel MM; Singh K
Anal Quant Cytol Histol; 2002 Aug; 24(4):205-11. PubMed ID: 12199321
[TBL] [Abstract][Full Text] [Related]
10. [The use of immunohistochemistry in the differential diagnosis of thyroid gland tumors with follicular growth pattern].
Laco J; Ryska A
Cesk Patol; 2006 Jul; 42(3):120-4. PubMed ID: 16955558
[TBL] [Abstract][Full Text] [Related]
11. [Expression of protooncogene bcl-2 in thyroid tumors].
Zhu J; Chen Y; Xue H
Zhonghua Yi Xue Za Zhi; 1996 Nov; 76(11):829-31. PubMed ID: 9275533
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
13. Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy.
Mehrotra P; Gonzalez MA; Johnson SJ; Coleman N; Wilson JA; Davies BR; Lennard TW
Laryngoscope; 2006 Aug; 116(8):1434-8. PubMed ID: 16885749
[TBL] [Abstract][Full Text] [Related]
14. Hyalinizing trabecular adenoma of the thyroid. A report of two cases with cytologic, histologic and immunohistochemical findings.
Kaleem Z; Dávila RM
Acta Cytol; 1997; 41(3):883-8. PubMed ID: 9167720
[TBL] [Abstract][Full Text] [Related]
15. MIB-1 immunohistometry of follicular adenoma and follicular carcinoma of the thyroid gland.
Rickert D; Mittermayer C; Lindenfelser R; Biesterfeld S
Anal Quant Cytol Histol; 2000 Jun; 22(3):229-34. PubMed ID: 10872040
[TBL] [Abstract][Full Text] [Related]
16. A study of FoxA1 expression in thyroid tumors.
Nonaka D
Hum Pathol; 2017 Jul; 65():217-224. PubMed ID: 28546130
[TBL] [Abstract][Full Text] [Related]
17. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis in thyroid neoplasms: relationship with p53 and bcl-2 expression.
Moore D; Ohene-Fianko D; Garcia B; Chakrabarti S
Histopathology; 1998 Jan; 32(1):35-42. PubMed ID: 9522214
[TBL] [Abstract][Full Text] [Related]
20. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.
Castelblanco E; Zafon C; Maravall J; Gallel P; Martinez M; Capel I; Bella MR; Halperin I; Temprana J; Iglesias C; Puig-Domingo M; Robledo M; Matias-Guiu X; Mauricio D
Thyroid; 2017 Jan; 27(1):59-66. PubMed ID: 27796194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
